Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.
best supportive care
oesophageal cancer
palliative treatment
real-world study
second line therapy
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
03
2021
accepted:
26
07
2021
entrez:
7
10
2021
pubmed:
8
10
2021
medline:
8
10
2021
Statut:
epublish
Résumé
The level of evidence for palliative second-line therapy in advanced esophageal squamous cell carcinoma (aESCC) is limited. This is the first study that reports efficacy data comparing second-line therapy + active symptom control (ASC) We conducted a tri-center retrospective cohort study ( The most frequent second-line regimens used were docetaxel (36%) and paclitaxel (18%). In unadjusted primary endpoint analysis, second-line + ASC was associated with significantly longer OS compared with ASC alone [hazard ratio (HR) = 0.49, 95% confidence interval (CI): 0.35-0.69, This real-world study supports the concept that systemic second-line therapy prolongs survival in patients with aESCC.
Sections du résumé
BACKGROUND
BACKGROUND
The level of evidence for palliative second-line therapy in advanced esophageal squamous cell carcinoma (aESCC) is limited. This is the first study that reports efficacy data comparing second-line therapy + active symptom control (ASC)
METHODS
METHODS
We conducted a tri-center retrospective cohort study (
RESULTS
RESULTS
The most frequent second-line regimens used were docetaxel (36%) and paclitaxel (18%). In unadjusted primary endpoint analysis, second-line + ASC was associated with significantly longer OS compared with ASC alone [hazard ratio (HR) = 0.49, 95% confidence interval (CI): 0.35-0.69,
CONCLUSION
CONCLUSIONS
This real-world study supports the concept that systemic second-line therapy prolongs survival in patients with aESCC.
Identifiants
pubmed: 34616490
doi: 10.1177/17588359211039930
pii: 10.1177_17588359211039930
pmc: PMC8488508
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359211039930Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Cancers (Basel). 2020 Aug 17;12(8):
pubmed: 32824580
Lancet Oncol. 2019 Nov;20(11):1506-1517
pubmed: 31582355
Eur J Surg Oncol. 2019 Feb;45(2):242-248
pubmed: 30031674
Eur J Cancer. 1997 Jul;33(8):1216-20
pubmed: 9301445
Onco Targets Ther. 2014 Oct 13;7:1875-81
pubmed: 25342911
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Chemother Pharmacol. 2011 Jun;67(6):1265-72
pubmed: 20703479
J Clin Oncol. 1996 Jan;14(1):164-70
pubmed: 8558192
Ann Oncol. 2009 Sep;20(9):1529-1534
pubmed: 19474114
BMC Cancer. 2019 Nov 29;19(1):1161
pubmed: 31783812
Nature. 2017 Jan 12;541(7636):169-175
pubmed: 28052061
Esophagus. 2019 Jan;16(1):25-43
pubmed: 30171414
Br J Cancer. 2008 Nov 4;99(9):1402-7
pubmed: 18971936
Cancer Chemother Pharmacol. 2014 Dec;74(6):1207-15
pubmed: 25267597
Stat Med. 2014 Mar 30;33(7):1242-58
pubmed: 24122911
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Sci Rep. 2019 Apr 3;9(1):5548
pubmed: 30944390
Br J Cancer. 2007 May 7;96(9):1348-52
pubmed: 17437008
Gastroenterology. 2018 Jan;154(2):360-373
pubmed: 28823862
Ann Surg Oncol. 2017 Jun;24(6):1596-1605
pubmed: 28108827
J Clin Oncol. 2011 Dec 10;29(35):4709-14
pubmed: 22067408
Adv Ther. 2020 Jul;37(7):3392-3403
pubmed: 32533533
Ann Oncol. 2004 Jan;15(1):64-9
pubmed: 14679122
Gut. 2015 Mar;64(3):381-7
pubmed: 25320104
Ann Oncol. 2019 Jan 1;30(1):34-43
pubmed: 30475943
Stat Med. 2002 Aug 15;21(15):2175-97
pubmed: 12210632
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883
pubmed: 31319389
Ann Oncol. 2004 Jun;15(6):955-9
pubmed: 15151954
Cancer Chemother Pharmacol. 2016 Dec;78(6):1209-1216
pubmed: 27778070
Clin Orthop Relat Res. 2017 May;475(5):1427-1435
pubmed: 28083752
Oncotarget. 2017 Oct 4;8(56):96048-96061
pubmed: 29221186
Anticancer Res. 2007 Jul-Aug;27(4C):2845-8
pubmed: 17695458
Br J Cancer. 2016 Nov 8;115(10):1264-1272
pubmed: 27764838
Ther Adv Med Oncol. 2020 Apr 10;12:1758835919900872
pubmed: 32313566